MeiraGTx (NASDAQ:MGTX) Receives “Buy” Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of MeiraGTx (NASDAQ:MGTX) in a report published on Monday,Benzinga reports. They currently have a $36.00 price objective on the stock.

Separately, Royal Bank of Canada lifted their price objective on MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th.

MeiraGTx Price Performance

Shares of MGTX stock opened at $5.92 on Monday. The firm’s 50 day moving average price is $5.28 and its two-hundred day moving average price is $4.82. The stock has a market cap of $462.65 million, a PE ratio of -4.89 and a beta of 1.24. MeiraGTx has a 52-week low of $3.85 and a 52-week high of $7.60. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34.

Institutional Investors Weigh In On MeiraGTx

Large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets increased its position in shares of MeiraGTx by 73.9% in the 1st quarter. BNP Paribas Financial Markets now owns 19,242 shares of the company’s stock valued at $117,000 after buying an additional 8,178 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of MeiraGTx by 1.9% in the first quarter. Russell Investments Group Ltd. now owns 157,999 shares of the company’s stock worth $959,000 after acquiring an additional 2,994 shares in the last quarter. Vanguard Group Inc. raised its position in shares of MeiraGTx by 3.7% during the first quarter. Vanguard Group Inc. now owns 323,891 shares of the company’s stock worth $1,966,000 after purchasing an additional 11,470 shares during the period. Acadian Asset Management LLC bought a new position in shares of MeiraGTx during the 1st quarter valued at about $25,000. Finally, EntryPoint Capital LLC grew its position in shares of MeiraGTx by 126,511.5% in the 1st quarter. EntryPoint Capital LLC now owns 32,919 shares of the company’s stock valued at $200,000 after purchasing an additional 32,893 shares during the period. Institutional investors own 67.48% of the company’s stock.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.